Portfolio company EIT Pharma received FDA acceptance of its New Drug Application for lonafarnib to treat chronic hepatitis D.
EIT Pharma is dedicated to developing transformative therapies for infectious diseases with high unmet needs, focusing on conditions such as Chronic Hepatitis D and Acute Respiratory Infection
EIT Pharma is dedicated to developing transformative therapies for infectious diseases with high unmet needs, focusing on conditions such as Chronic Hepatitis D and Acute Respiratory Infection.